Clinical trials: Cancer-related Pain
Uterine Fibroids, Leiomyoma
An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms
This is a 24-week, single-arm, open-label, virtual study evaluating the effects of Elix Cycle Balance and Elix Daily Harmony on uterine fibroid-related symptoms and quality of life in 42 participants.
- Conditions
- Uterine Fibroids, Leiomyoma, Menstrual Pain
- Trial name
- NCT07078682
- Testing
- Elix Daily Harmony
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Zenchi, Inc.
Breakthrough Cancer Pain
Patient Satisfaction and Quality of Life Impact - PecFent®
National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of…
- Trial name
- Qualipec (NCT01698645)
- Testing
- PecFent® (fentanyl) nasal spray
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Archimedes Development Ltd
Chronic Pain
The Effectiveness and Tolerability of Fentanyl Matrix in Chronic Non-cancer Pain; Assessment of Patient's Pain Treatment Goal Achievement
The purpose of this study is to assess the effectiveness and tolerability of Fentanyl matrix in chronic non-cancer pain.
- Trial name
- NCT01688583
- Testing
- Fentanyl matrix
- Where
- 11 sites in South Korea
- Volunteers
- 410 people
- Sponsor
- Janssen Korea, Ltd., Korea
Moderate-to-severe Chronic Noncancer Pain
Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain
The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.
- Trial name
- NCT02603705
- Testing
- Oxycodone extended-release
- Where
- 39 sites in United States
- Volunteers
- 281 people
- Sponsor
- Egalet Ltd
Cancer
Immediate-Release Oxycodone Capsules Study in Cancer Pain
The efficacy of dose titration of OxyNorm™(Oxycodone) immediate-release capsules versus morphine immediate-release tablets in the treatment of cancer pain.
- Trial name
- NCT01675622
- Testing
- Oxycodone, Morphine
- Volunteers
- 242 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Breakthrough Cancer Pain
Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain
Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. This is a phase I/IIa, pharmacokinetic, dose-response and safety study of inhaled fentanyl aerosol (25µg/dose) in Chinese patients with breakthrough…
- Trial name
- NCT04713189
- Testing
- Inhaled fentanyl aerosol
- Volunteers
- 96 people
- Sponsor
- Lee's Pharmaceutical Limited
Pain, Burning, Pain, Crushing
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain
The purpose of this study is to compare the safety and effectiveness of JNJ-42160443 with placebo in the treatment of chronic, moderate to severe cancer-related pain in terminally ill patients with a diagnosis of active cancer.
- Conditions
- Pain, Burning, Pain, Crushing, Pain, Migratory, Pain, Radiating
- Trial name
- NCT00929188
- Testing
- JNJ-42160443
- Where
- 40 sites in United States, France and 3 more
- Volunteers
- 100 people
- Sponsor
- Janssen Research & Development, LLC
Breakthrough Pain
Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units
Patients treated in Palliative Care Units are potentially fragile patients, especially in our case, which are cancer patients. The management of these patients is usually done from experience, because these patients rarely meet…
- Trial name
- CAVIDIOPAL (NCT02840500)
- Testing
- No intervention
- Where
- 10 sites in Spain
- Volunteers
- 101 people
- Sponsor
- Angelini Farmacéutica
Pain, Chronic
Ziconotide for Non-cancer Pain by Intrathecal Administration
Although ziconotide's marketing authorization does not restrict its use to a given type of pain, the drug has been used mainly in cancer patients.
- Trial name
- NCT06541184
- Testing
- Ziconotide [Prialt]
- Where
- 14 sites in France
- Volunteers
- 85 people
- Sponsor
- ESTEVE Pharmaceuticals SAS
Chronic Pain, Insomnia
The Efficacy of CALPXT96™in Improving Sleep Quality in Patients With Chronic Non-cancer Pain
California Poppy has been traditionally used in Herbal Medicine as an analgesic, mild sedative and/or sleep aid. However there are no human clinical trial data to support its use.
- Trial name
- CALPXT96 (NCT02232256)
- Testing
- CALPXT96
- Where
- Canada
- Sponsor
- 9305-9954 Quebec Inc
Bowel Dysfunction, Constipation
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one of 2 alvimopan arms, or to placebo.
- Trial name
- NCT00259922
- Testing
- Alvimopan, Alviompan
- Where
- 187 sites in United States, Australia and 10 more
- Volunteers
- 485 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cancer, Pain
An Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer Pain
The purpose of this study is to evaluate safety/tolerability and clinical utility of low-dose transdermal therapeutic system (TTS [medicated adhesive pad that is placed on the skin to deliver a timed-release dose of medication…
- Trial name
- NCT00771199
- Testing
- Transdermal Therapeutic System (TTS)-Fentanyl
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Janssen-Cilag Ltd.
Pain
Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic Pain
The purpose of this study was to characterize a safe and effective means of conversion and titration to an appropriate dose of hydromorphone HCI, to demonstrate comparable efficacy of OROS hydromorphone HCI SR (slow release) and…
- Trial name
- NCT00410943
- Testing
- OROS Hydromorphone HCI SR (slow release)
- Volunteers
- 169 people
- Sponsor
- Alza Corporation, DE, USA
Cancer Pain
Real-life Observational Study of Cancer Pain Management With Methadone
Study rational. Methadone is a distinctive opioid because of its pharmacological characteristics and its multiple modes of action, reinforcing its therapeutic value in managing advanced cancer pain, particularly in cases with a…
- Trial name
- DUNE (NCT05265442)
- Testing
- Methadone
- Where
- France
- Volunteers
- 136 people
- Sponsor
- RECORDATI GROUP
Pain, Advanced Cancer
A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer
The primary objective of this study was to evaluate the efficacy of nabiximols (Sativex®), compared with placebo, when used as an adjunctive measure in relieving uncontrolled persistent chronic pain (not breakthrough pain) in…
- Trial name
- NCT01424566
- Testing
- Nabiximols
- Where
- 65 sites in Australia, Bulgaria and 11 more
- Volunteers
- 406 people
- Sponsor
- Jazz Pharmaceuticals
Bowel Dysfunction, Constipation
Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1) to alvimopan or placebo.
- Trial name
- NCT00241722
- Testing
- Alvimopan
- Where
- 227 sites in United States, Australia and 15 more
- Volunteers
- 805 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Pain, Analgesics, Opioid
A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain
The purpose of this study was to characterize the steady-state pharmacokinetic (metabolism and action) profile of OROS hydromorphone HCI (slow release) in patients who required opioid therapy on a daily basis for chronic pain…
- Trial name
- NCT00410878
- Testing
- OROS Hydromorphone HCI (slow release)
- Volunteers
- 22 people
- Sponsor
- Alza Corporation, DE, USA
Pain
Pharmacokinetic (PK) Study of OxyNorm Injections in Chinese Patient
This is a single center, open label, randomized, parallel group single dose intravenous (i.v.) administration study. The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg.
- Trial name
- NCT01482936
- Testing
- Oxycodone (OxyNorm®) Injection
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Cancers, Pain, Lower Back Pain
Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy
The purpose of this study is to evaluate the long-term safety and tolerability of oxymorphone ER as an analgesic in cancer and lower back pain subjects having chronic moderate to severe pain.
- Trial name
- NCT00904280
- Testing
- Oxymorphone ER
- Where
- United States
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Pain
Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer
This study will evaluate the efficacy and safety of 4 mg zoledronic acid administered intravenously every 3-4 weeks in the treatment of bone metastases-related pain in patients with prostate cancer.
- Trial name
- TRAPEZE (NCT00375648)
- Testing
- Zoledronic acid
- Where
- France
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals